Shots: The P-IIb CYPRESS study evaluates the efficacy & safety of RSV vaccine vs PBO in a ratio (1:1) in 5782 patients aged ≥65 with LRTD caused by RSV The […]readmore
Tags : Lower Respiratory Tract Disease
Shots: The company initiates a P-III EVERGREEN study to evaluate the efficacy, safety & immunogenicity of RSV vaccine vs PBO in 23000 adults aged ≥60yrs. with LRTD caused by RSV […]readmore